Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 2 completion84d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — lenvatinib (Phase II Trial Completion)lenvatinib

Therapy area: Cardiovascular, Oncology. Indication: Hepatocellular Carcinoma, Thrombosis, Venous (Vein) Thrombosis

full page →lenvatinib →source: globaldata

Apr 30, 2026phase 2 completion84d agoMedical University of Gdansk — apixaban (Phase II Trial Completion)apixaban ODT

Therapy area: Cardiovascular, Oncology. Indication: Diffuse Large B-Cell Lymphoma, Hematological Tumor, Leukemia, Lymphoma, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Pulmonary Embolism, Thromboembolic Disease, Venous Thromboembolism

full page →apixaban ODT →source: globaldata

Apr 30, 2026phase 2 completion84d agoXijing Hospital — pertuzumab + trastuzumab (Phase II Trial Completion)pertuzumab + trastuzumab

Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Triple-Negative Breast Cancer (TNBC)

full page →pertuzumab + trastuzumab →source: globaldata

Apr 30, 2026phase 2 completion84d agoBeijing Sanbo Brain Hospital — ceritinib (Phase II Trial Completion)ceritinib

Therapy area: Oncology. Indication: Mesenchymal Tumor

full page →ceritinib →source: globaldata

Apr 30, 2026phase 2 completion84d agoWuhan Union Hospital — cadonilimab (Phase II Trial Completion)cadonilimab

Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)

full page →cadonilimab →source: globaldata

Apr 30, 2026phase 2 completion84d agoOhio State University Comprehensive Cancer Center — canakinumab (Phase II Trial Completion)canakinumab

Therapy area: Oncology. Indication: Lung Cancer

full page →canakinumab →source: globaldata

Apr 30, 2026phase 2 completion84d agoNational Cancer Institute US — ipilimumab (Phase II Trial Completion)ipilimumab

Therapy area: Oncology. Indication: Endometrial Cancer

full page →ipilimumab →source: globaldata

Apr 30, 2026phase 2 completion84d agoBioCanRx — ipilimumab (Phase II Trial Completion)ipilimumab

Therapy area: Oncology. Indication: Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma

full page →ipilimumab →source: globaldata

Apr 30, 2026phase 2 completion84d agoChinese Academy of Medical Sciences and Peking Union Medical College — fuzuloparib (Phase II Trial Completion)fuzuloparib

Therapy area: Oncology. Indication: Soft Tissue Sarcoma

full page →fuzuloparib →source: globaldata

Apr 30, 2026phase 2 completion84d agoSun Pharmaceutical Industries Ltd — Absorica (Phase II Trial Completion)ISOTRETINOIN

Therapy area: Oncology. Indication: Neuroblastoma

full page →ISOTRETINOIN →source: globaldata

Apr 30, 2026phase 2 completion84d agoArcus Biosciences Inc — atezolizumab (Phase II Trial Completion)atezolizumab

Therapy area: Oncology. Indication: Prostate Cancer

full page →atezolizumab →source: globaldata

Apr 30, 2026phase 2 completion84d agoHospital Of Dalian Medical University 1 — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 2 completion84d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — capecitabine (Phase II Trial Completion)capecitabine

Therapy area: Oncology. Indication: Colorectal Cancer

full page →capecitabine →source: globaldata

Apr 30, 2026phase 2 completion84d agoNanfang Hospital of Southern Medical University — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Small-Cell Lung Cancer

full page →adebrelimab →source: globaldata

← prev

page 4 of 4

Week of Apr 27, 2026